Amerita, Inc. is an authorized DME supplier for medicare equipments and products.
Amerita, Inc. is a Home Infusion Therapy Pharmacy in Houston, Texas. It is located at 4001 W Sam Houston Parkway N, Suite 120, Houston and it's customer support contact number is 713-843-7700. The authorized person of Amerita, Inc. is Melinda Silolahti who is Svp Revenue Cycle Management of the pharmacy and his contact number is 720-282-2382. Active license number of Amerita, Inc. is 25348 for Home Infusion Therapy Pharmacy in Texas. Amerita, Inc. accepts medicare which means medicare covered patients will not be billed for any more than the Medicare deductible and coinsurance. Amerita, Inc. is pharmacy-based, decentralized patient care organization with expertise in USP 797-compliant sterile drug compounding that provides care to patients with acute or chronic conditions generally pertaining to parenteral administration of drugs, biologics and nutritional formulae administered through catheters and/or needles in home and alternate sites. Extensive professional pharmacy services, care coordination, infusion nursing services, supplies and equipment are provided to optimize efficacy and compliance.
Pharmacy Details:
Amerita, Inc. type, location, contact phone number and fax are as below. Patients can directly walkin to the pharmacy or can call on the below given customer support phone number for enquiries.
Name:
Amerita, Inc.
Type:
Home Infusion Therapy Pharmacy
Location:
4001 W Sam Houston Parkway N, Suite 120, Houston, Texas, 77043-1237
Phone:
713-843-7700
Fax:
713-843-7705
Authorized/Official Person Profile:
Officially authorized person to contact for any management issues or complaints of this pharmacy is as below. Person's position and contact details are also mentioned below.
Name:
Melinda Silolahti
Position:
Svp Revenue Cycle Management
Contact Number:
720-282-2382
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of given pharmacy are as mentioned below.
NPI Number:
1396896395
NPI Enumeration Date:
16 Jan, 2007
NPI Last Update On:
06 Feb, 2024
Medical Licenses:
Organizations can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Amerita, Inc. are as mentioned below.
Specialization
License Number
State
Status
Home Infusion Therapy Pharmacy
25348
Texas
Primary
Durable Medical Equipment & Medical Supplies
Secondary
Parenteral & Enteral Nutrition
Secondary
Medical Foods Supplier
Secondary
Other Medical Identifiers:
Other legacy medical identifiers of the pharmacy such as Medicaid, Medicare PIN, NSC, UPIN etc. are mentioned as below.
Identifier
Type
State
Issuer
4543787
Other
Texas
Ncpdp
1396896395
Medicaid
Texas
25348
Other
Texas
Board Of Pharmacy
Medicare Enrollment:
Amerita, Inc. is enrolled in medicare and it's Pac Id, enrollment Id, registered name and type is as stated below.
PAC ID:
Enrollment ID:
Org Name
Medicare Entity Type
3375746464
O20100930044839
Amerita Inc
DME SUPPLIER - PHARMACY
Products Available:
Amerita, Inc. has following products available for sale under medicare.
Products
Enteral Equipment And/or Supplies
Enteral Nutrients
Infusion Pumps & Supplies: External Infusion
Infusion Pumps & Supplies: Implanted Infusion
Infusion Pumps & Supplies: Insulin Infusion
Parenteral Equipment And/or Supplies
Parenteral Nutrients
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
6912 S Quentin St Ste 50, Centennial, Colorado
Zip:
80112-4531
Phone Number:
720-282-5325
Fax Number:
877-676-0493
Patients can reach Amerita, Inc. at 4001 W Sam Houston Parkway N, Suite 120, Houston, Texas or can call on customer care at 713-843-7700.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 March, 2024.